Selected article for: "action novel mechanism and novel mechanism"

Author: Zimmerman, Danielle; Dang, Nam Hoang
Title: Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions
  • Cord-id: nzh9hay6
  • Document date: 2019_7_9
  • ID: nzh9hay6
    Snippet: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immunologic reactions to several stimuli, mostly medications, which present as a spectrum of primarily widespread mucocutaneous lesions, but also with other organ involvement. Pathology is characterized by full thickness necrosis of the epithelial layer of the involved organ due to immune-mediated apoptosis of the resident keratinocytes. High suspicion for early detection and quick withdrawal of the culprit medication are
    Document: Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are immunologic reactions to several stimuli, mostly medications, which present as a spectrum of primarily widespread mucocutaneous lesions, but also with other organ involvement. Pathology is characterized by full thickness necrosis of the epithelial layer of the involved organ due to immune-mediated apoptosis of the resident keratinocytes. High suspicion for early detection and quick withdrawal of the culprit medication are the most important steps in stopping this reaction. Aggressive supportive care is often necessary as the patient recovers. Steroids, other immunosuppressants, and plasmapheresis have all been studied as treatments, but high-quality evidence supporting their contributions, either together or separately, in decreasing length of hospital stay or prolonging survival have not been consistently demonstrated. Further studies of the mechanism of action and novel treatment modalities are still needed to improve outcomes in patients with this rare but often fatal condition.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and administration timing: 1
    • acute ards respiratory distress syndrome and low mortality rate: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute ards respiratory distress syndrome and lymphocyte group: 1, 2, 3, 4
    • additional treatment and administration timing: 1
    • additional treatment and lung cancer: 1, 2, 3, 4, 5
    • additional treatment and lymphocyte group: 1
    • administration timing and lung cancer: 1
    • long time period and low sample size: 1
    • low mortality rate and lung cancer: 1
    • low mortality rate and lymphocyte group: 1